ISEE / IVERIC bio (ISEE) Posts Positive Top-Line Data From GA Study

Naoki Okamura, chief executive officer of Japanese drugmaker Astellas Pharma Inc., discusses his company's decision to acquire Iveric Bio Inc., a de more_horizontal

Japan's Astellas agrees to pay $40 a share for Iveric, citing the potential of the biopharmaceutical company's ophthalmology programs. more_horizontal

Astellas Pharma Inc. said Monday that it agreed to acquire Iveric bio Inc. for about $5.9 billion to strengthen its capabilities in the ophthalmology more_horizontal

Against a relatively flat backdrop for the major equity indices, biotechnology firm Iveric Bio (NASDAQ: ISEE ) provided a decisively positive framewor more_horizontal

IVERIC bio, Inc. (NASDAQ:ISEE ) Q3 2022 Earnings Conference Call November 3, 2022 8:00 AM ET Company Participants Kathy Galante - SVP, IR & Corporate more_horizontal

IVERIC bio (ISEE) reports positive top-line data from the phase III GATHER2 study, evaluating its investigational candidate, Zimura, for the treatment more_horizontal

Positive results achieved in both GATHER1 and GATHER2 studies, whereby Zimura met prespecified primary endpoints of Mean rate of GA growth compared to more_horizontal

Source: Shutterstock / PopTika Iveric Bio (NASDAQ: ISEE ) stock is rising higher on Tuesday after the biopharmaceutical company revealed positive resu more_horizontal